Alpha Tau Treats First Patient with Recurrent Lung Cancer
10 Ottobre 2024 - 2:30PM
Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:
DRTS, DRTSW), the developer of the innovative alpha-radiation
cancer therapy Alpha DaRT®, announced today that its first patient
with recurrent lung cancer has been treated, in a clinical trial at
Hadassah Medical Center in Jerusalem, Israel.
The trial is designed to treat up to ten patients with recurrent
tumors in the mediastinum area of the chest, and allows for the use
of concurrent chemotherapy, targeted therapy, or immunotherapy, if
indicated. The study will assess the safety and feasibility of
delivering Alpha DaRT sources into the lung using an endobronchial
ultrasound (EBUS) procedure, including by observing the rate of
successful source placement and any treatment-related adverse
events. In addition, the study will also assess the efficacy of
Alpha DaRT for this indication by examining tumor response at one
and three months after source insertion using RECIST criteria, as
well as tumor coverage. Additional information about the trial can
be found at https://www.clinicaltrials.gov/study/NCT05632913.
According to the WHO’s International Agency for Research on
Cancer, lung cancer is the leading cause of cancer-related deaths
worldwide, with almost 2.5 million new cases detected each year,
and is often only diagnosed at advanced stages, when treatment
options are limited.In the U.S.,lung cancer is the third most
common cancer, according to the Centers for Disease Control and
Prevention, with an estimated 210,000 new cases per year.
“Alpha Tau continues to forge ahead with the application of
Alpha DaRT to a broader set of indications, particularly in tumors
in visceral organs and other complex cases,” said Alpha Tau Chief
Executive Officer Uzi Sofer. “As we see continued clinician
excitement and demand for use of the Alpha DaRT in an
ever-increasing set of cancers, the ability to start treating
patients in as terrible and widespread an illness as lung cancer is
particularly meaningful.”
“The Institute of Pulmonology of Hadassah Medical Center is
excited to utilize this groundbreaking EBUS-guided implantable
alpha radiation technology to treat a patient with lung cancer for
the first time,” noted Prof. Neville Berkman, MD, the study
principal investigator and Director of the Institute of Pulmonology
and Head of Adults and Invasive Pulmonology Unit, Hadassah Medical
Center, who treated the patient. “The treatment makes use of
bronchoscopic endobronchial ultrasound to insert the Alpha DaRT
sources. We look forward to further examining the promise of
what the Alpha DaRT treatment can offer lung cancer patients and
their families.”
“Treating the first lung patient with the Alpha DaRT is a very
exciting moment. We have already demonstrated the advantages of the
Alpha DaRT technology in a number of other tumor types, but
examining its application to an organ such the lung, given its
proximity to vital healthy organs, may hopefully open new doors to
a global population of patients with otherwise poor treatment
options,” commented Alpha Tau Chief Medical Officer Robert Den,
MD.
“Treating the first patient with lung
cancer using Alpha DaRT marks a significant advancement,
introducing a novel approach that combines the precision of
alpha-emitting particles with the ability to selectively target and
destroy tumor cells while minimizing damage to surrounding healthy
tissues,” added Dr. Philip Blumenfeld, study co-investigator and
Senior Radiation Oncologist and Head of Thoracic Radiation Oncology
Services at Hadassah Medical Center. “In this specific case, the
patient had already undergone conventional radiation therapy to the
lung and lymph nodes, and additional radiation would have posed a
high risk of serious harm to nearby structures, particularly the
esophagus and bronchus.”
About Alpha
DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is
designed to enable highly potent and conformal alpha-irradiation of
solid tumors by intratumoral delivery of radium-224 impregnated
sources. When the radium decays, its short-lived daughters are
released from the sources and disperse while emitting high-energy
alpha particles with the goal of destroying the tumor. Since the
alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims
to mainly affect the tumor, and to spare the healthy tissue around
it.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics
company that focuses on research, development, and potential
commercialization of the Alpha DaRT for the treatment of solid
tumors. The technology was initially developed by Prof. Itzhak
Kelson and Prof. Yona Keisari from Tel Aviv University.
Forward-Looking Statements
This press release includes "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. When used herein, words including "anticipate," "being,"
"will," "plan," "may," "continue," and similar expressions are
intended to identify forward-looking statements. In addition, any
statements or information that refer to expectations, beliefs,
plans, projections, objectives, performance or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking. All forward-looking
statements are based upon Alpha Tau's current expectations and
various assumptions. Alpha Tau believes there is a reasonable basis
for its expectations and beliefs, but they are inherently
uncertain. Alpha Tau may not realize its expectations, and its
beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking
statements as a result of various important factors, including,
without limitation: (i) Alpha Tau's ability to receive regulatory
approval for its Alpha DaRT technology or any future products or
product candidates; (ii) Alpha Tau's limited operating history;
(iii) Alpha Tau's incurrence of significant losses to date; (iv)
Alpha Tau's need for additional funding and ability to raise
capital when needed; (v) Alpha Tau's limited experience in medical
device discovery and development; (vi) Alpha Tau's dependence on
the success and commercialization of the Alpha DaRT technology;
(vii) the failure of preliminary data from Alpha Tau's clinical
studies to predict final study results; (viii) failure of Alpha
Tau's early clinical studies or preclinical studies to predict
future clinical studies; (ix) Alpha Tau's ability to enroll
patients in its clinical trials; (x) undesirable side effects
caused by Alpha Tau's Alpha DaRT technology or any future products
or product candidates; (xi) Alpha Tau's exposure to patent
infringement lawsuits; (xii) Alpha Tau's ability to comply with the
extensive regulations applicable to it; (xiii) the ability to meet
Nasdaq's listing standards; (xiv) costs related to being a public
company; (xv) changes in applicable laws or regulations; and the
other important factors discussed under the caption "Risk Factors"
in Alpha Tau's annual report filed on form 20-F with the SEC on
March 7, 2024, and other filings that Alpha Tau may make with the
United States Securities and Exchange Commission. These and other
important factors could cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent
management's estimates as of the date of this press release. While
Alpha Tau may elect to update such forward-looking statements at
some point in the future, except as required by law, it disclaims
any obligation to do so, even if subsequent events cause its views
to change. These forward-looking statements should not be relied
upon as representing Alpha Tau's views as of any date subsequent to
the date of this press release.
Investor Relations Contact:
IR@alphatau.com
Grafico Azioni Alpha Tau Medical (NASDAQ:DRTS)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Alpha Tau Medical (NASDAQ:DRTS)
Storico
Da Dic 2023 a Dic 2024